secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2026-08-13T12:23:31+00:00
Accession:  0001493152-26-037596
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q2 2026: $1.5M revenue, 2,770 EsoGuard tests, first LBM coverage policy
--------------------------------------------------------------------------------

- Q2 2026 EsoGuard revenue of $1.5M; 2,770 EsoGuard tests processed during the quarter.
- GAAP net loss ~$14.7M ($0.08/share) incl. $3.0M deemed preferred stock dividend; non-GAAP adjusted loss ~$10.9M ($0.06/share).
- Operating expenses ~$14.3M, including $1.7M stock-based compensation; cash $33.4M at June 30, 2026 vs $34.7M at Dec 31, 2025.
- Secured first laboratory benefit manager coverage policy from Concert (acquired by Lyric) recognizing EsoGuard as medically necessary for eligible patients.
- Developed health economic model showing improved clinical outcomes and cost-effectiveness; awaiting draft Medicare coverage policy for EsoGuard.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/0001493152-26-037596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315226037596/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-037596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer